接受双联抗血小板治疗的急性冠脉综合征人类免疫缺陷病毒感染患者的血小板反应性:EVERE2ST-HIV研究
EVERE2ST-HIV研究将80例感染HIV的急性冠脉综合征患者与160例未感染HIV的急性冠脉综合征患者按年龄、性别、糖尿病和双联抗血小板治疗匹配,评估血小板反应性。结果显示HIV感染患者对P2Y12抑制剂和阿司匹林的血小板反应性更高,高残留血小板反应性比例更高,且HIV感染与血小板反应性增高独立相关。
要点
- HIV感染的急性冠脉综合征患者对P2Y12抑制剂和阿司匹林的血小板反应性均高于未感染HIV者。
- HIV感染与高残留血小板反应性风险增高独立相关,对P2Y12抑制剂的OR值分别为7.6、2.06和2.91。
- 蛋白酶抑制剂的使用与血小板反应性增高和高残留血小板反应性比例增高相关。
核心结论
- 感染HIV的急性冠脉综合征患者对P2Y12抑制剂和阿司匹林的血小板反应性水平及高残留血小板反应性患病率均高于未感染HIV的患者。
研究设计与样本
- 研究纳入80例感染HIV的急性冠脉综合征患者,按年龄、性别、糖尿病和双联抗血小板治疗与160例未感染HIV的急性冠脉综合征患者进行匹配。
- 双联抗血小板治疗包括阿司匹林100%、氯吡格雷68%、普拉格雷31%、替格瑞洛1%。
- 急性冠脉综合征后超过30天,通过光透射聚集法测定对阿司匹林和P2Y12抑制剂的残留血小板聚集,并使用VerifyNow阿司匹林检测(ARU)、P2Y12检测(PRU)和VASP血小板反应性指数评估血小板反应性。
主要发现
- HIV感染患者对P2Y12抑制剂的残留血小板聚集为23.8 ± 2.7% vs 未感染HIV患者15.3 ± 1.3%(P = 0.001),PRU为132 ± 10 vs 107.4 ± 6.6(P = 0.04),VASP-PRI为45.2 ± 2.6% vs 32.0 ± 2.0%(P < 0.001)。
- HIV感染患者对阿司匹林的残留血小板聚集为3.6 ± 1.5% vs 未感染HIV患者0.4 ± 0.1%(P = 0.004),ARU为442 ± 11 vs 407 ± 5(P = 0.002)。
- 无论使用何种检测方法,HIV感染均与血小板反应性增高独立相关(RPA:P = 0.005;PRU:P < 0.001;VASP-PRI:P < 0.001)。
- HIV感染与对P2Y12抑制剂的高残留血小板反应性比例增高相关,OR分别为7.6(P < 0.001)、2.06(P = 0.06)和2.91(P = 0.004)。
- 阿司匹林相关结果与P2Y12抑制剂相似,蛋白酶抑制剂使用与血小板反应性增高及高残留血小板反应性比例增高相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To explore platelet reactivity on dual antiplatelet therapy (DAPT) of acute coronary syndrome (ACS) patients infected with HIV. METHODS AND RESULTS: Acute coronary syndrome patients infected with HIV (n = 80) were matched to ACS patients without HIV (n = 160) on age, sex, diabetes, and DAPT (aspirin 100%, clopidogrel 68%, prasugrel 31%, ticagrelor 1%). Platelet reactivity was evaluated after ACS (>30 days) by measuring residual platelet aggregation (RPA) to aspirin and to P2Y12 inhibitors with light transmission aggregometry (LTA), VerifyNow aspirin assay (ARU), and P2Y12 assay (PRU) and with the VASP platelet reactivity index (VASP-PRI). Proportion of patients with high residual platelet reactivity (HPR) was evaluated. HIV-infected ACS patients had higher levels of platelet reactivity in response to P2Y12 inhibitors (RPA: 23.8 ± 2.7% vs. 15.3 ± 1.3%; P = 0.001; PRU: 132 ± 10 vs. 107.4 ± 6.6; P = 0.04; and VASP-PRI: 45.2 ± 2.6% vs. 32.0 ± 2.0%; P < 0.001) and to aspirin (RPA: 3.6 ± 1.5% vs. 0.4 ± 0.1%; P = 0.004 and ARU: 442 ± 11 vs. 407 ± 5; P = 0.002) compared with non-HIV. HIV-infection was independently associated with increased platelet reactivity regardless of the test used (RPA: P = 0.005; PRU: P < 0.001 and VASP-PRI: P < 0.001) and a higher proportion of HPR (OR = 7.6; P < 0.001; OR = 2.06; P = 0.06; OR = 2.91; P = 0.004, respectively) in response to P2Y12 inhibitors. Similar results were found with aspirin. Protease inhibitors use was associated with increased platelet reactivity and higher rate of HPR. CONCLUSIONS: Acute coronary syndrome patients infected with HIV have increased levels of platelet reactivity and higher prevalence of HPR to P2Y12 inhibitors and aspirin than non-HIV patients. These results could provide potential explanations for the observed increase risk of recurrent ischemic events in the HIV-infected population.
引用
- Hauguel-Moreau M, Boccara F, Boyd A, et al. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. Eur Heart J. 2017. PMID: 28065907. doi:10.1093/eurheartj/ehw583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。